1. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128:343-50.
2. Degos F, Perez R Roche B, Mahmoudi A, Asselineau J, Voitot H et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013-21.
3. Crespo G, Fernandez-Varo G, Marino Z, Casals G, Miquel R, Martinez SM, et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: a prospective study. J Hepatol. 2012;57:281-7.
4. Loomba R and Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut 2020:69:1343-52.
5. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43:1317-25.
6. Tamaki N, Kurosaki M, Tanaka K, Suzuki Y, Hoshioka Y, Kato T, et al. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepat 2013:20:72-6.
7. Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019:156:1264-81.e4.
8. Kuno A, Sato T, Shimazaki H, Unno S, Saitou K, Kiyohara K, et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013:7:642-647.
9. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M,
Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates
fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.
10. Hanai T, Shiraki M, Ohnishi s, Miyazaki T, Ideta T, Kochi T, et al. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res. 2015;45:1083-90.
11. Ura K, Furusyo N, Ogawa E, Hayashi T, Mukae H, Shimizu M, et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C. Aliment Pharmacol Ther. 2016;43:114-24.
12. Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol. 2015;50:76-84.
13. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018:53:819-26.
14. Yamasaki K, Tateyama M, Abiru S, Komori A, Nagaoka S, Saeki A, et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014:60:1563-70.
15. Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels and liver fibrosis: a meta-analysis. J Gastroenterol Hepatol 2017;32:1922-30.
16. Gebo KA, Herlong HF, Torbenson MS, Jenckes MW, Chander G, Ghanem KG, El-Kamary SS, Sulkowski M, Bass EB. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology. 2002;36:S161-S72.
17. Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol. 2015;21:11567-83.
18. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-973.
19. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, Yokosuka O, Suzuki H. New Inuyama Classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 1996;6:112-119.
20. Goodman ZD. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007;47:598-607.
21. de Lédinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr. 2007;45:443-50.
22. El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, El-Sayed HM, et al. Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic
hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol
Hepatol. 2010;22:946-51.
23. Yamada N, Sanada Y, Tashiro M, Hirata Y, Okada N, Ihara Y, et al. Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia. J Gastroenterol. 2017;52:245-52.
24. Behairy OG, El-Gendy SA, Ibrahim DY, Mansour AI, El-Shimi OS. Mac-2 binding protein glycan isomer as noninvasive tool to assess liver fibrosis in children
with chronic liver disease. Hepatol Res. 2021;51:277-283.
25. Kage M, Fujisawa T, Shiraki K, Tanaka T, Fujisawa T, Kimura A, et al. Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan. Hepatology. 1997;26:771-5.
26. Mizuochi T, Takano T, Yanagi T, Ushijima K, Suzuki M, Miyoshi Y, et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J Gastroenterol. 2018;53:419-426.